A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases

New England Journal of Medicine

Volumn 339, Issue 8, 1998, Pages 504-510

  Roddy, Ronald E ^a,d   Zekeng, Léopold ^c   Ryan, Kelley A ^a   Tamoufé, Ubald ^c   Weir, Sharon S ^a   Wong, Emelita L ^b  

^a Epidemiology   (United States)

^b Division of Biostatistics   (United States)

^c MINISTRY OF PUBLIC HEALTH   (Cameroon)

^d FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONOXINOL 9; PLACEBO;

ADULT; ARTICLE; CAMEROON; CHLAMYDIASIS; CLINICAL TRIAL; COLPOSCOPY; CONDOM; CONTROLLED STUDY; DNA PROBE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GONORRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL; SEXUALLY TRANSMITTED DISEASE;

ACQUIRED IMMUNODEFICIENCY SYNDROME--PREVENTION AND CONTROL; AFRICA; AFRICA SOUTH OF THE SAHARA; BIOLOGY; CAMEROON; CASE CONTROL STUDIES; CHLAMYDIA--PREVENTION AND CONTROL; CONTRACEPTION; CONTRACEPTIVE AGENTS--THERAPEUTIC USE; DEVELOPING COUNTRIES; DISEASES; FAMILY PLANNING; FRENCH SPEAKING AFRICA; GENITAL EFFECTS, FEMALE; GENITALIA; GENITALIA, FEMALE; GONORRHEA--PREVENTION AND CONTROL; HIV INFECTIONS--PREVENTION AND CONTROL; INFECTIONS; MIDDLE AFRICA; NONOXYNOL-9--THERAPEUTIC USE; PHYSIOLOGY; REPRODUCTIVE TRACT INFECTIONS; RESEARCH METHODOLOGY; RESEARCH REPORT; SEXUALLY TRANSMITTED DISEASES; SPERMICIDAL CONTRACEPTIVE AGENTS--THERAPEUTIC USE; STUDIES; UROGENITAL SYSTEM; VIRAL DISEASES;

ADULT; ANTI-INFECTIVE AGENTS; CHLAMYDIA INFECTIONS; CONDOMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOUBLE-BLIND METHOD; FEMALE; GENITAL DISEASES, FEMALE; GONORRHEA; HIV INFECTIONS; HUMANS; MALE; NONOXYNOL; PROPORTIONAL HAZARDS MODELS; PROSTITUTION; SEXUALLY TRANSMITTED DISEASES; SPERMATOCIDAL AGENTS;

EID: 0032552228     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808203390803     Document Type: Article

References (26)

1. Singh B, Cutler JC, Utidjian HMD. Studies on the development of a vaginal preparation providing both prophylaxis against venereal disease and other genital infections and contraception. II. Effect in vitro of vaginal contraceptive and non-contraceptive preparations on Treponema pallidum and Neisseria gonorrhoeae. Br J Vener Dis 1972;48:57-64.
2. Bolch OH Jr, Warren JC. In vitro effects of Emko on Neisseria gonorrhoeae and Trichomonas vaginalis. Am J Obstet Gynecol 1973;115:1145-8.
3. Benes S, McCormack WM. Inhibition of growth of Chlamydia trachomatis by nonoxynol-9 in vitro. Antimicrob Agents Chemother 1985;27:724-6.
4. Kelly JP, Reynolds RB, Stagno S, Louv WC, Alexander WJ. In vitro activity of the spermicide nonoxynol-9 against Chlamydia trachomatis. Antimicrob Agents Chemother 1985;27:760-2.
5. Judson FN, Ehret JM, Bodin GF, Levin MJ, Rietmeijer CAM. In vitro evaluations of condoms with and without nonoxynol 9 as physical and chemical barriers against Chlamydia trachomatis, herpes simplex virus type 2, and human immunodeficiency virus. Sex Transm Dis 1989;16:51-6.
6. Jones BM, Geary I, Lee ME, Duerden BI. Susceptibility of Haemophilus ducreyi to spermicidal compounds, in vitro. Genitourin Med 1991;67: 268-9.
7. Singh B, Posti B, Cutler JC. Virucidal effect of certain chemical contraceptives on type 2 herpesvirus. Am J Obstet Gynecol 1976;126:422-5.
8. Asculai SS, Weis MT, Rancourt MW, Kupterberg AB. Inactivation of herpes simplex viruses by nonionic surfactants. Antimicrob Agents Chemother 1978;13:686-90.
9. Roddy RE, Schulz KF, Cates W Jr. Microbicides, meta-analysis, and the N-9 question: where's the research? Sex Transm Dis 1998;25:151-3.
10. Louv WC, Austin H, Alexander WJ, Stagno S, Cheeks J. A clinical trial of nonoxynol-9 for preventing gonococcal and chlamydial infections. J Infect Dis 1988;158:518-23.
11. Niruthisard S, Roddy RE, Chutivongse S. Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infections. Lancet 1992;339:1371-5.
12. Kreiss J, Ngugi E, Holmes KK, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992;268:477-82.
13. Barbone F, Austin H, Louv WC, Alexander WJ. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol 1990;163:510-4.
14. Hicks DR, Martin LS, Getchell JP, et al. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro. Lancet 1985;2:1422-3.
15. Polsky B, Baron PA, Gold JWM, Smith JL, Jensen RH, Armstrong D. In vitro inactivation of HIV-1 by contraceptive sponge containing nonoxynol-9. Lancet 1988;1:1456.
16. Malkovsky M, Newell A, Dalgleish AG. Inactivation of HIV by nonoxynol-9. Lancet 1988;1:645.
17. Rietmeijer CAM, Krebs JW, Feorino PM, Judson FN. Condoms as physical and chemical barriers against human immunodeficiency virus. JAMA 1988;259:1851-3.
18. Miller CJ, Alexander NJ, Gettie A, Hendrickx AG, Marx PA. The effect of contraceptives containing nonoxynol-9 on the genital transmission of simian immunodeficiency virus in rhesus macaques. Ferril Steril 1992; 57:1126-8.
19. Moench TR, Whaley KJ, Mandrell TD, Bishop BD, Witt CJ, Cone RA. The cat/feline immunodeficiency virus model for transmucosal transmission of AIDS: nonoxynol-9 contraceptive jelly blocks transmission by an infected cell inoculum. AIDS 1993;7:797-802.
20. Zekeng L, Feldblum PJ, Oliver RM, Kaptue L. Barrier contraceptive use and HIV infection among high-risk women in Cameroon. AIDS 1993; 7:725-31.
21. Hira SK, Feldblum PJ, Kamanga J, Mukelabai G, Weir SS, Thomas JC. Condom and nonoxynol-9 use and the incidence of HIV infection in serodiscordant couples in Zambia. Int J STD AIDS 1997;8:243-50.
22. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
23. Mauck CK, Allen S, Baker JM, Barr SP, Abercrombie T, Archer DF. An evaluation of the amount of nonoxynol-9 remaining in the vagina up to 4 h after insertion of a vaginal contraceptive film (VCF) containing 70 mg nonoxynol-9. Contraception 1997;56:103-10.
24. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
25. For women only: what women can do to protect themselves from AIDS. Albany: New York State Department of Health, 1994 (brochure).
26. Turner CF, Miller HG. Zenilman's anomaly reconsidered: fallible reports, ceteris paribus, and other hypotheses. Sex Transm Dis 1997;24:522-7.